| Identification | |
| Name: | FLUVASTATIN SODIUM |
| Synonyms: | fluvastatin sodium salt; sodium (3r,5s,6e)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1h-indol-2-yl]-3,5-dihydroxy-6-heptenoate |
| CAS: | 93957-55-2 |
| Molecular Formula: | C24H25FNNaO4 |
| Molecular Weight: | 433.45 |
| InChI: | InChI=1/C24H26FNO4.Na/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30;/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30);/q;+1/p-1/b12-11+;/t18-,19-;/m0./s1 |
| Molecular Structure: | ![(C24H25FNNaO4) fluvastatin sodium salt; sodium (3r,5s,6e)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1h-indol-2-yl]-3,...](https://img.guidechem.com/casimg/93957-55-2.gif) |
| Properties | |
| Melting Point: | 194-197oC |
| Appearance: | Light yellow solid powder |
| Specification: | Yellow Powder usageEng:A synthetic HMG-CoA reductase inhibitor. Antilipemic |
| Biological Activity: | Orally active, potent and competitive HMG-CoA reductase inhibitor (IC 50 = 40 -100 nM at human liver microsomes). Inhibits vascular smooth muscle proliferation in vitro (IC 50 = 70 nM) and exhibits antihypercholesterolemic and antioxidant activity in vivo . |
| Usage: | A synthetic HMG-CoA reductase inhibitor. Antilipemic |
| Safety Data | |
 |
|
